Kathmandu, September 11
Sopan Pharmaceuticals Limited’s net profit has fallen by more than 82 percent within a year. According to the company’s unaudited fourth-quarter financial statement for FY 2025/26, the company posted a net profit of Rs 3.8289 crore.
In the same period of the previous fiscal year, the company’s net profit stood at Rs 21.7791 crore. This marks an 82.42 percent decline in profit. The company says the pressure on profit came from a decline in other income and a rise in selling, distribution, and administrative expenses, even though operating income saw modest growth.
The company’s operating income rose from Rs 50.05 crore to Rs 51.14 crore, a growth of about 2.18 percent. However, other income fell sharply from Rs 1.57 crore to just Rs 12.33 lakh, a decline of about 92 percent.
The company’s financial expenses fell during the review period, dropping from Rs 5.68 crore in the previous fiscal year to Rs 4.39 crore. However, even as financial expenses fell, operating expenses rose. The company’s selling and distribution expenses increased from Rs 4.07 crore to Rs 6.44 crore, a rise of about 58 percent.
Similarly, administrative expenses rose from Rs 4.27 crore to Rs 6.20 crore, an increase of about 45 percent. Thus, despite modest revenue growth, the sharp decline in other income combined with rising operating expenses appears to have significantly reduced the company’s profit.
Along with profit, the company’s earnings per share (EPS) also fell significantly, from Rs 18.33 in the previous fiscal year to Rs 2.23 in the review period, a decline of about 87.83 percent.
By the end of the review period, the company’s net worth per share stood at Rs 96.34, and total assets per share were valued at Rs 157.82.
The financial statement notes that the company’s reserves and accumulated fund stood at Rs 36.73 crore.
